International Isotopes INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
OQB
Radnostix Inc. has issued its proxy statement for the 2026 Annual Meeting of Shareholders, detailing proposals for director elections, auditor ratification, and an incentive plan.
OQB
International Isotopes Inc. is changing its corporate name to Radnostix, Inc. to reflect its strategic shift towards radiopharma and theranostics in healthcare.
OQB
International Isotopes Inc. has filed definitive additional proxy materials (DEFA14A) with the U.S. Securities and Exchange Commission.
OQB
International Isotopes Inc. has scheduled its 2025 Annual Meeting of Shareholders to vote on the election of directors, ratification of its accounting firm, executive compensation, and a proposed reverse stock split ranging from 1-for-50 to 1-for-275 to boost share price and facilitate major exchange listing.
OQB
International Isotopes Inc. has filed a definitive proxy statement with the SEC.
OQB
International Isotopes Inc. will hold its 2024 Annual Meeting of Shareholders on July 10, 2024, to elect directors and ratify the appointment of its independent registered public accounting firm.